A citation-based method for searching scientific literature


List of co-cited articles
1703 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
787
67






Identification of a serotonin/glutamate receptor complex implicated in psychosis.
Javier González-Maeso, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, Graeme Milligan,[...]. Nature 2008
563
29

A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
Michael A Benneyworth, Zixiu Xiang, Randy L Smith, Efrain E Garcia, P Jeffrey Conn, Elaine Sanders-Bush. Mol Pharmacol 2007
127
27

Pharmacology and functions of metabotropic glutamate receptors.
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
26

Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
26

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).
Michael P Johnson, David Barda, Thomas C Britton, Renee Emkey, William J Hornback, G Erik Jagdmann, David L McKinzie, Eric S Nisenbaum, Joseph P Tizzano, Darryle D Schoepp. Psychopharmacology (Berl) 2005
126
26

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Linda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, Craig R Salhoff, Jeffrey M Witkin, Kenneth W Perry, Kelly I Griffey, Joseph P Tizzano, James A Monn, David L McKinzie,[...]. Psychopharmacology (Berl) 2007
129
26



Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
John H Krystal, Walid Abi-Saab, Edward Perry, D Cyril D'Souza, Nianjin Liu, Ralitza Gueorguieva, Lisa McDougall, Tracy Hunsberger, Aysenil Belger, Louise Levine,[...]. Psychopharmacology (Berl) 2005
207
24

Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
P Jeffrey Conn, Craig W Lindsley, Carrie K Jones. Trends Pharmacol Sci 2009
267
24

Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
Ruggero Galici, Carrie K Jones, Kamondanai Hemstapat, Yi Nong, Nicholas G Echemendia, Lilly C Williams, Tomas de Paulis, P Jeffrey Conn. J Pharmacol Exp Ther 2006
129
24

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
24


A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
176
24


Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Eduardo Dunayevich, Janelle Erickson, Louise Levine, Ronald Landbloom, Darryle D Schoepp, Gary D Tollefson. Neuropsychopharmacology 2008
147
22

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
22

Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Chantal Schlumberger, Daniela Schäfer, Caroline Barberi, Lorenzo Morè, Jens Nagel, Małgorzata Pietraszek, Werner J Schmidt, Wojciech Danysz. Behav Pharmacol 2009
68
30

Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine.
Michael P Johnson, Melvyn Baez, G Erik Jagdmann, Thomas C Britton, Thomas H Large, David O Callagaro, Joseph P Tizzano, James A Monn, Darryle D Schoepp. J Med Chem 2003
150
20


Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
G J Marek, R A Wright, D D Schoepp, J A Monn, G K Aghajanian. J Pharmacol Exp Ther 2000
227
20

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.
Chad J Swanson, Mark Bures, Michael P Johnson, Anni-Maija Linden, James A Monn, Darryle D Schoepp. Nat Rev Drug Discov 2005
464
18

LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.
Darryle D Schoepp, Rebecca A Wright, Louise R Levine, Brenda Gaydos, William Z Potter. Stress 2003
173
18

Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.
Daniel S Lorrain, Hervé Schaffhauser, Una C Campbell, Christopher S Baccei, Lucia D Correa, Blake Rowe, Dana E Rodriguez, Jeffery J Anderson, Mark A Varney, Anthony B Pinkerton,[...]. Neuropsychopharmacology 2003
80
21




Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Linda M Rorick-Kehn, Bryan G Johnson, Jennifer L Burkey, Rebecca A Wright, David O Calligaro, Gerard J Marek, Eric S Nisenbaum, John T Catlow, Ann E Kingston, Deborah D Giera,[...]. J Pharmacol Exp Ther 2007
80
20

The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat.
Caitlin A Jones, Angus M Brown, Dorothee P Auer, Kevin C F Fone. Psychopharmacology (Berl) 2011
72
22


Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat.
Gabor Imre, Amber Salomons, Minke Jongsma, Dirk S Fokkema, Johan A Den Boer, Gert J Ter Horst. Pharmacol Biochem Behav 2006
52
28

A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.
Gene G Kinney, Julie A O'Brien, Wei Lemaire, Maryann Burno, Denise J Bickel, Michelle K Clements, Tsing-Bau Chen, David D Wisnoski, Craig W Lindsley, Philip R Tiller,[...]. J Pharmacol Exp Ther 2005
245
15


Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats.
Agnieszka Nikiforuk, Piotr Popik, Karla U Drescher, Marcel van Gaalen, Ana-Lucia Relo, Mario Mezler, Gerard Marek, Hans Schoemaker, Gerhard Gross, Anton Bespalov. J Pharmacol Exp Ther 2010
59
25

Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
878
15


Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2.
Hervé Schaffhauser, Blake A Rowe, Sylvia Morales, Laura E Chavez-Noriega, Ruoyuan Yin, Christine Jachec, Sara P Rao, Gretchen Bain, Anthony B Pinkerton, Jean-Michel Vernier,[...]. Mol Pharmacol 2003
136
14

ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
Feng Liu, Steve Grauer, Cody Kelley, Rachel Navarra, Radka Graf, Guoming Zhang, Peter J Atkinson, Michael Popiolek, Caitlin Wantuch, Xavier Khawaja,[...]. J Pharmacol Exp Ther 2008
161
14


Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.
Michael F Egan, Richard E Straub, Terry E Goldberg, Imtiaz Yakub, Joseph H Callicott, Ahmad R Hariri, Venkata S Mattay, Alessandro Bertolino, Thomas M Hyde, Cynthia Shannon-Weickert,[...]. Proc Natl Acad Sci U S A 2004
297
14

Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent.
Guy A Higgins, Theresa M Ballard, James N C Kew, J Grayson Richards, John A Kemp, Geo Adam, Thomas Woltering, Shigetada Nakanishi, Vincent Mutel. Neuropharmacology 2004
132
14




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.